Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 8.9% in the morning ... Access our full analysis report here, it’s free. Incyte’s shares are not very volatile and ...

Technically, INCY is currently below its 30-week EMA, with short-term bearish momentum but long-term bullish momentum, making it a cautious buy. Volume analysis shows neutral institutional ...

Recall that in Q3 and Q4 2023, we saw a significant increase in the number of Medicare Part D patients receiving free product. As we anticipated, these patients returned to paid demand in 2024.

Incyte (INCY) came out with quarterly earnings of $1.43 per share, missing the Zacks Consensus Estimate of $1.53 per share. This compares to earnings of $1.06 per share a year ago. These figures ...

Truist Financial analyst Srikripa Devarakonda reiterated a Hold rating on Incyte (INCY – Research Report) today. The company’s shares closed yesterday at $68.30. Leverage the power of TipRanks ...

Incyte Stock Performance Shares of INCY stock opened at $74.13 on Monday. Incyte Co. has a one year low of $50.35 and a one year high of $83.95. The company has a debt-to-equity ratio of 0.01, a ...

Before you invest in Incyte Corporation (INCY), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.

Incyte (INCY) reported $1.18 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 16.3%. EPS of $1.43 for the same period compares to $1.06 a year ago.

Incyte Price Performance INCY opened at $68.30 on Tuesday. The stock’s 50-day moving average price is $71.79 and its 200 day moving average price is $69.18. Incyte Co. has a 12-month low of $50. ...